Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Scope Fluidics Spolka Akcyjna's EV-to-EBIT or its related term are showing as below:
WAR:SCP'
s EV-to-EBIT Range Over the Past 10 Years
Min: -124.92 Med: -15.34 Max: 4.98
Current: -6.35
During the past 10 years, the highest EV-to-EBIT of Scope Fluidics Spolka Akcyjna was 4.98. The lowest was -124.92. And the median was -15.34.
WAR:SCP's EV-to-EBIT is ranked worse than 100% of 105
companies
in the Medical Diagnostics & Research industry
Industry Median: 24.25
vs WAR:SCP: -6.35
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Scope Fluidics Spolka Akcyjna's Enterprise Value for the quarter that ended in Mar. 2026 was zł313.92 Mil.
Scope Fluidics Spolka Akcyjna's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł-46.76 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scope Fluidics Spolka Akcyjna EV-to-EBIT Related Terms
Scope Fluidics Spolka Akcyjna EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Scope Fluidics Spolka Akcyjna's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scope Fluidics Spolka Akcyjna EV-to-EBIT vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Scope Fluidics Spolka Akcyjna's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Scope Fluidics Spolka Akcyjna's EV-to-EBIT falls into.
Scope Fluidics Spolka Akcyjna's current Enterprise Value is zł296.85 Mil.
Scope Fluidics Spolka Akcyjna's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł-46.76 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scope Fluidics Spolka Akcyjna (WAR:SCP) has a EV-to-EBIT of -6.35 as of Aug. 14, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Scope Fluidics Spolka Akcyjna and its competitors. According to the industry distribution chart, Scope Fluidics Spolka Akcyjna ranks #999999 out of 105 companies in the Medical Diagnostics & Research industry.
Is Scope Fluidics Spolka Akcyjna's EV-to-EBIT too high?
Scope Fluidics Spolka Akcyjna's current EV-to-EBIT is -6.35. Based on the distribution chart, Scope Fluidics Spolka Akcyjna ranks #999999 out of 105 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Scope Fluidics Spolka Akcyjna has a GF Score™ of 47/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Scope Fluidics Spolka Akcyjna's EV-to-EBIT compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Scope Fluidics Spolka Akcyjna ranks #999999 out of 105 companies for EV-to-EBIT. This places Scope Fluidics Spolka Akcyjna in the lower half of its industry. The industry median EV-to-EBIT is 24.25. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Diagnostics & Research company?
The median EV-to-EBIT among Medical Diagnostics & Research companies is 24.25, based on 105 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Scope Fluidics Spolka Akcyjna and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-EBIT is 24.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scope Fluidics Spolka Akcyjna's current EV-to-EBIT is -6.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scope Fluidics Spolka Akcyjna stock overvalued right now?
Based on GuruFocus' analysis, Scope Fluidics Spolka Akcyjna (WAR:SCP) is currently considered Fairly Valued. The stock's GF Value™ is zł126.70, compared to a current price of zł136.60 — trading 7.8% above its estimated fair value. The current EV-to-EBIT is -6.35. Scope Fluidics Spolka Akcyjna's overall GF Score™ is 47/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Scope Fluidics Spolka Akcyjna (WAR:SCP), the current EV-to-EBIT is -6.35 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Scope Fluidics Spolka Akcyjna (WAR:SCP) Overvalued in 2026?
Based on GuruFocus' analysis, Scope Fluidics Spolka Akcyjna stock appears to be overvalued.
The current stock price of zł136.60 is trading 7.8% above its estimated GF Value™ of zł126.70.
GuruFocus considers Scope Fluidics Spolka Akcyjna to be Fairly Valued.
Key valuation signals for WAR:SCP:
EV-to-EBIT: -6.35
GF Value™: zł126.70 vs. price of zł136.60 (7.8% above fair value)
No single metric tells the full story. See the WAR:SCP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Scope Fluidics Spolka Akcyjna focuses on global challenges in health to develop diagnostic and med tech solutions. The company combines the expertise in microfluidic technology with the awareness of the challenges in medical diagnostics. It provides prototyping support for diagnostic services.
47GF Score
Get the complete analysis for WAR:SCP
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:SCP has been successfully added to your 
